Clinical Trials Logo

Chronic Myeloid Leukemia clinical trials

View clinical trials related to Chronic Myeloid Leukemia.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04360005 Available - Clinical trials for Chronic Myeloid Leukemia

Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase

Start date: n/a
Phase:
Study type: Expanded Access

This program provides access to asciminib for patients with CML in chronic phase (CP) without documented T315I mutation after failure to or intolerance of two prior TKI OR patients in CML-CP with documented T315I mutation and without comparable or satisfactory alternative therapy to treat the disease

NCT ID: NCT00854841 Available - Clinical trials for Chronic Myeloid Leukemia

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Start date: n/a
Phase: N/A
Study type: Expanded Access

Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) subjects who are imatinib failures or who have achieved only a suboptimal response after 3-18 months (12-77 weeks) of therapy with imatinib 400 mg. Primary Objective: The primary objective of this study is to compare the rate of CCyR of dasatinib (100mg QD) to high-dose imatinib (600 mg QD) therapy at 6 months after randomization in CP Ph+ CML subjects who are imatinib failures or who have achieved only a suboptimal response after 3 - 18 months of imatinib monotherapy at 400 mg/day.